Belgium's UCB in autoimmune drug deal with Antengene

Core Viewpoint - Belgian drugmaker UCB has entered into a licensing agreement with Antengene for the experimental autoimmune disease therapy ATG-201, involving an upfront payment of $60 million and potential additional payments exceeding $1.1 billion based on milestone achievements [1]. Company Summary - UCB has secured a worldwide license for ATG-201, which targets B-cell-related autoimmune diseases, and will oversee its development, manufacturing, and commercialization [1]. - Antengene plans to submit clinical trial applications for ATG-201 in Australia and China in the first quarter of 2026, with further development to be transferred to UCB after completing phase I trials [1]. Financial Terms - The agreement includes an upfront fee of $60 million, with additional payments contingent on specific conditions and milestones, as well as royalties based on net sales [1]. - The total potential value of the deal could exceed $1.1 billion if certain milestones are met [1].